Literature DB >> 25898815

Poorly differentiated oncocytic (hürthle cell) follicular carcinoma: an institutional experience.

Shuting Bai1, Zubair W Baloch, Teresa D Samulski, Kathleen T Montone, Virginia A LiVolsi.   

Abstract

The proposed diagnostic criteria for poorly differentiated thyroid carcinoma (known as the Turin classification) were defined based on growth pattern (solid, trabecular, or insular) and high-grade morphologic features (nuclear pleomorphism, mitoses including abnormal forms, and coagulative tumor necrosis). The development of this classification specifically did not include tumors with oncocytic or Hürthle cell cytology, and only sparse literature describing poorly differentiated oncocytic carcinomas is available. In this study, we examined a cohort of 284 cases of oncocytic follicular carcinoma/Hürthle cell carcinoma (OFC/HCC) and identified 17 cases of oncocytic variant of poorly differentiated carcinoma (OV-PDTC) based on Turin criteria. Compared to minimally invasive and angioinvasive OFC/HCC, these tumors arose in older patients (range 44-88 years; average 71 years), were larger (average size 4.5 cm), and all had extensive vascular invasion (5-15 foci), and coagulative tumor necrosis and the tumor cells were arranged in a trabecular or solid growth pattern. All showed an admixture of oncocytic follicular/Hürthle cells arranged in solid and trabecular growth pattern. Aggregates of small sized cells with minimal eosinophilic cytoplasm, comprising 10-20% of the entire tumor mass were also seen in 16/17 cases. Clinical follow-up was available in 12 cases and ranged from 6 to 120 months (average 41 months). Distant metastases were seen in 10/12 (83%) patients; two had lung and one had bone metastases at the time of thyroid surgery, and four subsequently developed cervical lymph node metastases. Two patients died of disease, and ten are alive either with or free of tumor. The OV-PDTC is a distinct entity which can be identified based on Turin criteria and the presence of a distinct "small cell" component. It is frequently associated with regional recurrence and distant metastases and can lead to tumor-related demise.

Entities:  

Mesh:

Year:  2015        PMID: 25898815     DOI: 10.1007/s12022-015-9367-6

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  30 in total

1.  Poorly differentiated carcinoma of the thyroid gland.

Authors:  D K GRANNER; J A BUCKWALTER
Journal:  Surg Gynecol Obstet       Date:  1963-06

2.  Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid.

Authors:  M Papotti; B Torchio; L Grassi; A Favero; G Bussolati
Journal:  Am J Surg Pathol       Date:  1996-06       Impact factor: 6.394

3.  Oncocytic (Hürthle cell) tumors of the thyroid: distinct growth patterns comparedẁith clinicopathological features.

Authors:  S Lazzi; D Spina; C Als; P Tosi; L Mazzucchelli; R Kraft; J A Laissue; H Cottier
Journal:  Thyroid       Date:  1999-02       Impact factor: 6.568

4.  Malignant potential of small oncocytic follicular carcinoma/Hürthle cell carcinoma: an institutional experience.

Authors:  Teresa Danielle Samulski; Shuting Bai; Virginia A LiVolsi; Kathleen Montone; Zubair Baloch
Journal:  Histopathology       Date:  2013-08-19       Impact factor: 5.087

5.  Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland.

Authors:  S Pilotti; P Collini; L Mariani; M Placucci; I Bongarzone; P Vigneri; S Cipriani; F Falcetta; R Miceli; M A Pierotti; F Rilke
Journal:  Am J Surg Pathol       Date:  1997-12       Impact factor: 6.394

6.  Hürthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study.

Authors:  M A Sobrinho-Simões; J M Nesland; R Holm; M C Sambade; J V Johannessen
Journal:  Ultrastruct Pathol       Date:  1985       Impact factor: 1.094

7.  Hürthle cell tumors: a twenty-five-year experience.

Authors:  M Arganini; R Behar; T C Wu; F Straus; M McCormick; L J DeGroot; E L Kaplan
Journal:  Surgery       Date:  1986-12       Impact factor: 3.982

8.  Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy.

Authors:  G Har-El; T Hadar; K Segal; R Levy; J Sidi
Journal:  Cancer       Date:  1986-04-15       Impact factor: 6.860

9.  Poorly differentiated forms of papillary thyroid carcinoma: distinctive entities or morphological patterns?

Authors:  S Pilotti; P Collini; A Manzari; E Marubini; F Rilke
Journal:  Semin Diagn Pathol       Date:  1995-08       Impact factor: 3.464

10.  Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients.

Authors:  Marco Volante; Stefania Landolfi; Luigi Chiusa; Nicola Palestini; Manuela Motta; Alessandra Codegone; Bruno Torchio; Mauro G Papotti
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860

View more
  8 in total

Review 1.  Overview of the 2022 WHO Classification of Thyroid Neoplasms.

Authors:  Zubair W Baloch; Sylvia L Asa; Justine A Barletta; Ronald A Ghossein; C Christofer Juhlin; Chan Kwon Jung; Virginia A LiVolsi; Mauro G Papotti; Manuel Sobrinho-Simões; Giovanni Tallini; Ozgur Mete
Journal:  Endocr Pathol       Date:  2022-03-14       Impact factor: 3.943

Review 2.  Aggressive variants of follicular cell-derived thyroid carcinoma: an overview.

Authors:  Cristina Pizzimenti; Vincenzo Fiorentino; Antonio Ieni; Maurizio Martini; Giovanni Tuccari; Maria Lentini; Guido Fadda
Journal:  Endocrine       Date:  2022-07-21       Impact factor: 3.925

3.  Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases.

Authors:  Bin Xu; Julia David; Snjezana Dogan; Iñigo Landa; Nora Katabi; Maelle Saliba; Anjanie Khimraj; Eric J Sherman; Robert Michael Tuttle; Giovanni Tallini; Ian Ganly; James A Fagin; Ronald A Ghossein
Journal:  Histopathology       Date:  2021-10-07       Impact factor: 7.778

4.  PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma.

Authors:  Shuanzeng Wei; Virginia A LiVolsi; Kathleen T Montone; Jennifer J D Morrissette; Zubair W Baloch
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

Review 5.  Pitfalls in Thyroid Cytopathology.

Authors:  Esther Diana Rossi; Adebowale J Adeniran; William C Faquin
Journal:  Surg Pathol Clin       Date:  2019-12

6.  Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.

Authors:  Jelena Lukovic; Irina Petrovic; Zijin Liu; Susan M Armstrong; James D Brierley; Richard Tsang; Jesse D Pasternak; Karen Gomez-Hernandez; Amy Liu; Sylvia L Asa; Ozgur Mete
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-16       Impact factor: 5.555

7.  PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study.

Authors:  Soledad Cameselle-García; Sámer Abdulkader-Sande; María Sánchez-Ares; Gemma Rodríguez-Carnero; Jesús Garcia-Gómez; Francisco Gude-Sampedro; Ihab Abdulkader-Nallib; José Manuel Cameselle-Teijeiro
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

Review 8.  Genetics, Diagnosis, and Management of Hürthle Cell Thyroid Neoplasms.

Authors:  David G McFadden; Peter M Sadow
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-10       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.